Browse the evidence

GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.

Research suggests GLP-1 medications may help protect against Alzheimer's and Parkinson's disease by reducing brain inflammation. While not yet a standard treatment for these conditions, ongoing clinical trials are investigating their use. If you have risk factors for cognitive decline, discussing these emerging benefits with your doctor may be relevant, especially if you are already using GLP-1s for diabetes or weight management.

Genetic predisposition to higher gut microbial butyrate production potential is causally linked to improved insulin response during an oral glucose tolerance test, while higher fecal propionate levels are causally linked to an increased risk of type 2 diabetes.

Your genetics influence how your gut bacteria process fiber into metabolites. While butyrate production is linked to better insulin response, high levels of propionate in stool have been causally linked to a higher risk of type 2 diabetes in genetic studies. This highlights the complexity of gut health beyond just 'eating fiber'.

The exponential decay of energy intake suppression during obesity pharmacotherapy is caused by a physiological proportional feedback control system that increases appetite in proportion to weight loss, rather than a diminishing direct effect of the drug itself.

If you are taking obesity medication and your weight loss slows down after a few months, it is likely due to your body's natural physiological resistance to losing weight, not necessarily because the drug has stopped working. This is a predictable part of the process described by proportional feedback control. Maintaining the medication as prescribed may still be beneficial for long-term weight management, even if the rate of loss decreases.

FGF21 is a liver-derived hormone that coordinates metabolic and behavioral responses to protein restriction and macronutrient imbalance, specifically driving changes in macronutrient choice.

This is a mechanistic insight. It suggests that the body has specific hormonal signals (like FGF21) that drive cravings for specific nutrients (like protein) when imbalanced. This explains why 'hunger' can be specific to certain foods, not just total calories.

Broader access to antiobesity medications (AOM) generates substantial societal value through reduced comorbidities, increased productivity, and improved quality of life, despite current low uptake rates.

For policymakers and payers, expanding access to AOM is a high-value investment. The study shows that increasing uptake to 15-30% among eligible adults generates trillions in societal value through reduced healthcare costs, fewer comorbidities, and better productivity. This supports policy changes to remove barriers to AOM access.

Leucine-enriched whey protein supplementation (20g whey + 3g leucine) post-exercise does not provide additional benefits for sarcopenia, muscle mass, or myokine concentrations compared to resistance training alone in post-hospitalized older adults over 12 weeks.

You do not need to buy leucine-enriched protein supplements to support your resistance training. The study shows that taking 20g of whey protein with 3g of leucine after training did not improve muscle mass or sarcopenia outcomes more than training alone. Save your money and focus on consistent training.

GLP-1 receptor agonists may provide direct anti-inflammatory and disease-modifying benefits to osteoarthritic joints, independent of weight loss, by reducing pro-inflammatory cytokines and protecting chondrocytes.

Beyond helping you lose weight, GLP-1 medications might directly protect your knee joints from wear and tear. Research suggests these drugs can reduce inflammation within the joint itself and slow down cartilage loss, even independent of weight changes. This means you might experience less pain and slower progression of osteoarthritis, making these drugs a potentially dual-purpose treatment for both obesity and joint health.

High-fructose corn syrup intake impairs insulin response in the skeletal muscle vasculature and contributes to insulin resistance.

Reduce intake of high-fructose corn syrup found in processed foods and sugary drinks. While clinical trials are still clarifying the exact cardiovascular risk, evidence suggests that high fructose intake directly impairs how your blood vessels respond to insulin.

Oral superabsorbent hydrogel (OSH) administration prevents diet-induced obesity and metabolic syndrome in mice by preserving gut barrier integrity and expanding Akkermansia muciniphila.

This research suggests that a specific type of hydrogel, when taken with meals, may help prevent weight gain and metabolic issues by protecting the gut lining and encouraging the growth of beneficial bacteria (A. muciniphila). While promising in mice, this is not yet a proven human therapy. Focus on proven methods like diet and exercise for now.

OSH administration improves metabolic parameters, including glucose tolerance and insulin sensitivity, by increasing GLP-1 levels and protecting the intestinal barrier.

This study indicates that OSH may help regulate blood sugar and insulin levels in mice by boosting GLP-1. This is a potential benefit for metabolic health, but more research is needed to see if it applies to humans.

OSH administration expands Akkermansia muciniphila abundance in the gut microbiota, which is associated with improved metabolic health.

This study shows that OSH can increase the levels of Akkermansia muciniphila, a bacterium linked to better metabolic health, in mice. This is a promising area of research, but it is not yet a proven strategy for humans.

Semaglutide use is associated with acute kidney injury (AKI), specifically acute interstitial nephritis (AIN) and podocytopathies (FSGS/MCD), particularly in patients with pre-existing chronic kidney disease (CKD) or advanced age.

If you are taking semaglutide and notice swelling, changes in urination, or fatigue, report it to your doctor immediately, especially if you have existing kidney disease. Most cases of kidney injury from semaglutide are reversible if the drug is stopped early and treated with steroids.

Long-acting GLP-1 receptor agonist (Ex-4)2-Fc promotes adipose tissue browning and thermogenesis in high-fat diet mice by enriching gut Lactobacillus reuteri and reducing serum ceramide levels via upregulation of alkaline ceramidase 2 (Acer2).

This research suggests that GLP-1 agonists do more than just suppress appetite; they actively change how fat tissue works by promoting 'browning' (heat production) and improving lipid metabolism. This effect is linked to changes in gut bacteria (specifically Lactobacillus reuteri) and the reduction of harmful lipids called ceramides. For individuals considering GLP-1 therapy, this highlights that the drug works through complex biological pathways beyond just eating less, potentially offering metabolic benefits even at lower doses when combined with healthy gut flora.

Combining GLP-1 receptor agonists with myostatin or activin type II receptor inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) preserves or increases lean mass while enhancing fat loss, addressing the risk of sarcopenia and metabolic slowdown associated with standard AOM therapy.

Current GLP-1 therapies can lead to muscle loss, which may hinder long-term weight maintenance. Emerging combination therapies that pair GLP-1 agonists with muscle-preserving antibodies (like bimagrumab or myostatin inhibitors) show promise in preclinical models for doubling fat loss while increasing lean mass. Patients should discuss these emerging options with their providers, especially if they are concerned about muscle loss.

Weight regain after discontinuation of GLP-1-based AOMs is an inherent feature of current pharmacological strategies, but future interventions such as gene therapy (GLP-1PGTx) or gradual dose-tapering may mitigate this by sustaining hormonal signals or allowing hormonal adaptation.

Stopping GLP-1 medications currently leads to weight regain for most people due to hormonal adaptations. While lifestyle changes help, they may not be enough to counteract these hormonal shifts. Future treatments, such as gene therapy or careful dose-tapering, aim to sustain weight loss after stopping, but these are not yet standard care. Patients should plan for long-term management strategies with their providers.

Combined GIPR/GLP1R agonism lowers plasma triglyceride levels by increasing VLDL turnover (reduced hepatic VLDL-TG production and increased uptake by adipose tissue and liver).

Dual GIP/GLP-1 agonism improves lipid profiles by accelerating the clearance of triglyceride-rich lipoproteins (VLDL). This suggests that patients on these therapies may see significant improvements in triglyceride levels, which is a key risk factor for cardiovascular disease.

Combined GIPR/GLP1R agonism reduces systemic low-grade inflammation, evidenced by lower hepatic inflammatory markers and circulating adhesion molecules (ICAM-1, VCAM-1).

Dual GIP/GLP-1 therapy may help reduce chronic, low-grade inflammation associated with obesity and cardiovascular risk. This anti-inflammatory effect is part of the mechanism by which these drugs may protect blood vessels.

GLP-1 receptor agonists (GLP-1RAs) exert neuroprotective effects in neurodegenerative diseases (Alzheimer's, Parkinson's, Multiple Sclerosis) by modulating synaptic plasticity, reducing neuroinflammation, and promoting neurogenesis, although clinical trial outcomes remain variable.

GLP-1 drugs like semaglutide and liraglutide show promise in protecting brain cells and slowing cognitive/motor decline in diseases like Alzheimer's and Parkinson's, based on strong lab studies. However, human trials have been mixed, likely due to how patients are chosen and how trials are run. If you have a neurodegenerative condition, discuss with your doctor whether the potential brain benefits outweigh the risk of stomach side effects, especially if you are frail or elderly.

Novel GLP-1 receptor agonists (e.g., NLY01, tirzepatide) are being developed to enhance central nervous system penetration and efficacy, with some showing specific benefits in younger patient subgroups.

Newer GLP-1 drugs like NLY01 and tirzepatide are being designed to work better in the brain. Early results suggest they might help younger patients more than older ones. If you are interested in these treatments, ask your doctor about the latest clinical trials and whether a newer agent might be suitable for your specific condition and age.

Higher expression of the adipose (adp/WDTC1) gene in human subcutaneous adipose tissue is associated with lower body fat mass and enhanced insulin sensitivity.

This research identifies a specific gene (adp/WDTC1) in fat tissue that correlates with being leaner and more insulin sensitive. While you cannot directly 'dose' this gene, understanding that higher expression is linked to better metabolic health may inform future therapeutic targets for obesity and diabetes management.

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a statistically significant increase in the dispensing of antidepressants, suggesting a potential adverse effect on mood or mental health.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that there is a statistically higher chance you might be prescribed an antidepressant. This does not mean everyone will experience mood issues, but it is a known risk signal. Monitor your mental health closely, especially if you have a history of depression, and discuss any mood changes with your doctor immediately.

AMPK activation suppresses leptin secretion in adipocytes independently of adipogenesis and adipocyte maturity, challenging the view that AMPK's primary benefit is promoting adipose expansion.

While exercise and certain drugs activate AMPK to help store fat healthily, this research highlights that AMPK also directly reduces leptin, a hormone that tells your brain you're full. In obesity, high leptin levels cause resistance. By suppressing leptin secretion, AMPK activation might help restore the body's natural ability to feel full, offering a pathway to treat leptin resistance without just focusing on fat storage.

The Elipse swallowable intragastric balloon does not produce clinically significant weight loss or diabetes control in patients with obesity class 1-2 and type 2 diabetes when used in a real-world setting with standard nutritional follow-up.

If you have obesity and type 2 diabetes, this specific swallowable balloon is not a reliable standalone solution for significant weight loss in a standard healthcare setting. It resulted in only ~4% weight loss at 16 weeks, which is minimal compared to surgical options. It may be considered only if you strictly adhere to intensive dietary counseling and accept modest results, but it is not a substitute for more effective interventions.

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.